注册 登录  
   显示下一条  |  关闭
温馨提示!由于新浪微博认证机制调整,您的新浪微博帐号绑定已过期,请重新绑定!立即重新绑定新浪微博》  |  关闭






Metformin might block prostate cancer progression二甲双胍可能阻断前列腺癌进展  

2013-11-14 15:41:43|  分类: 二甲双胍 |  标签: |举报 |字号 订阅

  下载LOFTER 我的照片书  |

By: M. ALEXANDER OTTO, Internal Medicine News Digital Network

Metformin appears to have slowed, or perhaps even halted, the progression of prostate cancer in a retrospective, Canadian study of 3,837 diabetic men.

The study was published in the Journal of Clinical Oncology.

The longer the men were on the drug, the better they did; for each additional 6 months of treatment following diagnosis, prostate cancer mortality dropped 24% (adjusted hazard ratio 0.76). There was a 24% reduction in all-cause mortality in the first 6 months, as well (aHR, 0.76), but the association faded with time; 24-30 months out from diagnosis, metformin was associated with an all-cause mortality reduction of 7% (aHR, 0.93).

Although some of the men used other diabetes drugs such as sulfonylureas, thiazolidinediones, and insulin some of the time, only metformin improved prostate cancer outcomes, regardless of concomitant cancer treatments.

"We cannot conclude" that a nondiabetic population would see similar benefits, but the results "suggest that metformin may ... improve survival as an adjunct therapy, even among those already receiving optimal cancer treatments. We believe an interventional study of the use of metformin to delay progression in prostate cancer is warranted," wrote Dr. David Margel, a uro-oncology fellow at the University of Toronto when the study was conducted, and now a urologist at the Rabin Medical Center in Petah-Tikva, Israel (J. Clin. Oncol. 2013 Aug 5 [doi: 10.1200/JCO.2012.46.7043]).

Dr. Margel and his team are not the first to suggest that the ubiquitous diabetes drug might also be a potent cancer fighter. Metformin is being tested in dozens of trials not only for prostate tumors, but also for breast, brain, lung, uterine, colorectal, pancreatic, skin, blood, and thyroid cancers.

It probably doesn’t stop benign cells from turning cancerous, but may "influence cancer cells indirectly by decreasing insulin levels or directly by influencing cancer cell proliferation and apoptosis," the investigators wrote.

Study data came from health care databases kept by the province of Ontario, including the Ontario Cancer Registry and Ontario Diabetes Database.

The men were a median of 75 years old at diagnosis, and followed for a median of 4.64 years. About a quarter (976) presented with high-grade tumors, and almost 60% (2,167) with high-volume tumors. Thirty-five percent (1,343) died during the study period; prostate cancer was responsible for 7.6% (291) of the deaths.

"Overall, 1,251 (32.6%) and 1,619 (42.2%) were exposed to metformin before and after [prostate cancer] diagnosis, respectively. Patients were exposed to metformin for a median of 19 months before diagnosis and 8.9 months after diagnosis," Dr. Margel and his team noted.

The Ontario Ministry of Health and Long-Term Care funded the project. The authors have no conflicts of interest.

View on the News

It’s time for a clinical trial

The authors provide a convincing case for a causal interpretation ... [and] a compelling rationale for conducting a large-scale long-term randomized trial of metformin in men with clinically localized disease. The potential benefits of metformin could exceed those of existing drug therapies, particularly given its safety profile. Based on the strong evidence of this well-executed study, metformin ... may potentially be a safe and effective secondary prevention strategy for prostate cancer (J. Clin. Oncol. 2013 Aug 5 [doi: 10.1200/JCO.2013.50.7715]).

Interestingly, although postdiagnostic use of metformin was highly significant, the association of cumulative metformin use before prostate cancer diagnosis with prostate cancer death was null. As prostate cancer date of diagnosis is a rather arbitrary point in the progression of the disease, this discrepancy between the impact of pre- and postdiagnostic use is perplexing and warrants further study.

Kathryn Penney, Sc.D., is a medical epidemiologist at Brigham and Women’s Hospital in Boston. Dr. Meir Stampfer is professor of nutrition and epidemiology at Harvard Medical School, Boston. They reported no relevant conflicts of interest.

加拿大一项对3,837例男性糖尿病患者的回顾性研究显示,二甲双胍似乎可延缓、甚至阻断前列腺癌的进展。该研究发表于《临床肿瘤学杂志》(J. Clin. Oncol. 2013 Aug 5 [doi: 10.1200/JCO.2012.46.7043])。


该研究的数据来自安大略省保管的医疗保健数据库,包括安大略肿瘤注册和安大略糖尿病数据库。这些男性患者诊断前列腺癌时的中位年龄为75岁,中位随访4.64年。约有1/4(976例)表现为高级别肿瘤,接近60%(2,167例)为大体积肿瘤。35%(1,343例)的患者于研究期间死亡;7.6%(291例)的死亡原因为前列腺癌。“总之,分别有1,251例 (32.6%)和1,619 例(42.2%)患者在诊断前列腺癌之前和之后暴露于二甲双胍。诊断前的中位暴露时间为19个月,诊断后的中位暴露时间为8.9个月,”主要研究者David Margel医生及其团队指出。

结果显示,接受二甲双胍治疗的时间越长,对前列腺癌进展的阻止作用越强;在诊断后每多治疗6个月,前列腺癌死亡率降低24%[校正危险比(aHR)为0.76]。在最初的6个月内,全因死亡率降低了24%(aHR, 0.76),但相关性随时间进展而减弱;在诊断后24~30个月,二甲双胍与全因死亡率降低7% (aHR, 0.93)相关。尽管一些男性患者使用其他降糖药物,如磺脲类、噻唑烷二酮类等,有时也会使用胰岛素,但仅二甲双胍可改善前列腺癌预后,并且与合并抗肿瘤治疗无关。


Margel医生在研究期间担任多伦多大学的泌尿肿瘤科研究员,目前为以色列Petah-Tikva Rabin医学中心的泌尿科医生。


阅读(139)| 评论(0)
推荐 转载




<#--最新日志,群博日志--> <#--推荐日志--> <#--引用记录--> <#--博主推荐--> <#--随机阅读--> <#--首页推荐--> <#--历史上的今天--> <#--被推荐日志--> <#--上一篇,下一篇--> <#-- 热度 --> <#-- 网易新闻广告 --> <#--右边模块结构--> <#--评论模块结构--> <#--引用模块结构--> <#--博主发起的投票-->


网易公司版权所有 ©1997-2018